Plain Language Summary
What is this summary about?
HARMONi is a study of a new treatment for people with advanced or metastatic non–small cell lung cancer (NSCLC) with an activating mutation in the epidermal growth factor receptor (EGFR) gene. The study included participants in Asia, Europe, and North America whose cancer had gotten worse after treatment with an EGFR tyrosine kinase inhibitor (EGFR-TKI).
Ivonescimab is a new type of cancer treatment that helps the immune system recognize and attack tumor cells. It also blocks the formation of new blood vessels that tumors need to grow. HARMONi compared ivonescimab plus chemotherapy with placebo plus chemotherapy.
What were the results?
Participants who were given ivonescimab plus chemotherapy lived longer without their cancer getting worse or spreading (called progression-free survival). The median progression-free survival was 6.8 months with ivonescimab plus chemotherapy compared with 4.4 months with placebo plus chemotherapy. This difference was statistically significant. The median overall survival, or the amount of time participants lived after starting treatment, was longer with ivonescimab plus chemotherapy (median, 16.8 months) compared with placebo plus chemotherapy (median, 14.0 months); however, this difference was not statistically significant.
Two hundred and seven of 218 participants (95%, or about 9 out of every 10) who were given ivonescimab plus chemotherapy and 203 of 218 participants (93%, or about 9 out of every 10) who were given placebo plus chemotherapy had side effects related to their treatment. Common side effects with ivonescimab plus chemotherapy included changes in blood cell levels, nausea, decreased appetite, vomiting, and changes in liver enzymes. Some participants in each treatment group had severe or serious side effects. Four participants who received ivonescimab plus chemotherapy and five who received placebo plus chemotherapy died from treatment-related side effects.
What do the results mean?
For participants whose advanced NSCLC had gotten worse after EGFR-TKI treatment, ivonescimab plus chemotherapy resulted in a reduced risk of cancer getting worse or spreading by nearly half, compared with placebo plus chemotherapy. Overall survival was longer with ivonescimab plus chemotherapy; however, the difference was not statistically significant. Side effects occurred in a similar proportion of participants in both treatment groups. Most side effects could be managed without significantly impacting the participants’ quality of life or requiring treatment discontinuation.
Clinical trial number: NCT06396065
KEYWORDS: clinical trial, HARMONi, HARMONi-A ivonescimab, non-small cell lung cancer, plain language summary
Infographic
Infographic:

A PDF version of this infographic is available as supplemental material.
Acknowledgments
The authors thank the participants and their caregivers, the investigators, and all the site staff who have participated and who are participating in this study.
Supplementary Material
This is an abstract of the Plain Language Summary of Publication article.
To read the full Plain Language Summary of this article, click here to view the PDF.
Link to original article here
Disclosure statement
XL discloses consulting or advisory fees from AbbVie, Abion, Akeso, Allist, ArriVent Biopharma, AstraZeneca, Avistone, Bayer, BioNTech, BlossomHill, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Dizal, Eli Lilly, EMD Serono (Merck KGaA), Hengrui, Innovent, Johnson & Johnson (Janssen), Merck, Novartis, Pfizer, Regeneron, Summit Therapeutics, SystImmune, Taiho, and Teligene; and research funding to her institution from ArriVent Biopharma, Dizal, Eli Lilly, EMD Serono, Johnson & Johnson (Janssen), Regeneron, Takeda, Teligene, and Thermo Fisher. AP discloses consulting fees from ArriVent Biopharma, AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Janssen, Johnson & Johnson, Gilead, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer, Roche/Genentech, Mundipharma, and Summit Therapeutics; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or education events from AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, eCancer, Medscape, Takeda, Janssen, Johnson & Johnson, Merck Sharp & Dohme, PeerVoice, PeerView, and TouchOncology. JLa discloses honoraria from Roche Canada, Eli Lilly, and Pfizer; participation in advisory boards and/or to give academic teaching lecture sessions to BeOne; and research funding to Roche Canada. DR-A discloses personal fees or honoraria for consultancy or advisory roles and lectures from Roche/Genentech, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Amgen, Merck Sharp & Dohme, Merck Serono, Eli Lilly, Pfizer, Summit Therapeutics, Gilead, GlaxoSmithKline, Pharma Mar, Incyte, Takeda, Regeneron, Novartis, Pierre Fabre, and Johnson & Johnson; and travel expenses from Roche/Genentech, Bristol Myers Squibb, Merck Sharp & Dohme, and AstraZeneca. AC discloses grants or contracts from Merck Sharp & Dohme and Pfizer; consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche/Genentech, Takeda, BeiGene, Summit Therapeutics, Amgen, Janssen, Regeneron, and Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or education events from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Pierre Fabre, and PharmaMar; and support for attending meetings and/or travel from Boehringer Ingelheim, Merck Sharp & Dohme, Roche, Pfizer, and AstraZeneca. LB discloses consulting fees from Johnson & Johnson, Revolution Medicines, AbbVie, Eli Lilly, Bristol Myers Squibb, Pfizer, Nuvalent, Taiho Oncology, Summit Therapeutics, Bayer, Boehringer Ingelheim, Genentech, Natera, Merck, AnHeart Therapeutics, AstraZeneca, Regeneron, Novocure, Daiichi Sankyo, Sanofi, Gilead, Teligene, Neuvogen, and BioAtla. GLR discloses consulting fees from Merck Sharp & Dohme, Regeneron, Roche, Eli Lilly, Bristol Myers Squibb, Amgen, AstraZeneca, Johnson & Johnson, Merck, Novartis, Pierre Fabre, Bayer, BeOne, Pfizer, Takeda, GlaxoSmithKline, Daiichi Sankyo, and Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Merck Sharp & Dohme, Regeneron, Roche, Eli Lilly, Bristol Myers Squibb, Amgen, AstraZeneca, Johnson & Johnson, Merck, Novartis, Pierre Fabre, Bayer, BeOne, Pfizer, Takeda, GlaxoSmithKline, Daiichi Sankyo, and Sanofi; support for attending meetings and/or travel from Merck Sharp & Dohme, Regeneron, Roche, Eli Lilly, Bristol Myers Squibb, Amgen, AstraZeneca, Johnson & Johnson, Merck, Novartis, Pierre Fabre, Bayer, BeOne, Pfizer, Takeda, GlaxoSmithKline, Daiichi Sankyo, and Sanofi; and participation in Data Safety Monitoring Board or Advisory Board for Merck Sharp & Dohme, Regeneron, Roche, Eli Lilly, Bristol Myers Squibb, Amgen, AstraZeneca, Johnson & Johnson, Merck, Novartis, Pierre Fabre, Bayer, BeOne, Pfizer, Takeda, GlaxoSmithKline, Daiichi Sankyo, Sanofi, and Gilead. NBL discloses grants or research support (institutional) from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Eli Lilly, Guardant Health, Johnson & Johnson, Merck Sharp & Dohme, NeoGenomics, Novartis, Pfizer, and Takeda; travel support (CME lectures) from AstraZeneca, Merck Sharp & Dohme, Roche, Johnson & Johnson, Sanofi, and Guardant Health; and participation in Data Safety Monitoring Board (uncompensated) for Mirati Therapeutics and Daiichi Sankyo. FCa discloses grants or contracts from Roche, AstraZeneca, Bristol Myers Squibb, Pfizer, Takeda, Eli Lilly, Bayer, Amgen, Sanofi, PharmaMar, Novocure, Mirati Therapeutics, Galecto, OSE, Illumina, BioNTech, Pierre Fabre, and Merck Sharp & Dohme; consulting fees from Roche, AstraZeneca, Bristol Myers Squibb, Pfizer, Takeda, Eli Lilly, Bayer, Amgen, Sanofi, PharmaMar, Novocure, Mirati Therapeutics, Galecto, OSE, Illumina, BioNTech, Pierre Fabre, and Merck Sharp & Dohme; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche, AstraZeneca, Bristol Myers Squibb, Pfizer, Takeda, Eli Lilly, Bayer, Amgen, Sanofi, PharmaMar, Novocure, Mirati Therapeutics, Galecto, OSE, Illumina, BioNTech, Pierre Fabre, and Merck Sharp & Dohme. NG discloses research grants or support to his institution from AbbVie, Amgen, AstraZeneca, BeOne, Boehringer Ingelheim, Bayer, BioNTech, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Johnson & Johnson, Eli Lilly, Sivan, and Taiho; consultancy fees from AbbVie, Accord, Amgen, AstraZeneca, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Ipsen, Johnson & Johnson, Eli Lilly, Merck Sharp & Dohme, Natera, Pfizer, PharmaMar, Pierre Fabre, Regeneron, and Summit Therapeutics; speakers bureau fees for AbbVie, Amgen, AstraZeneca, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Merck Sharp & Dohme, and Novocure; hospitality from Bristol Myers Squibb, Johnson & Johnson, and Pierre Fabre; and employment at AstraZeneca (family member). SP discloses consulting fees from AnHeart Therapeutics, Amgen, Arcus Biosciences, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Ellipses, Erasca, Gilead, GlaxoSmithKline, Guardant Health, IO Biotech, Janssen, Eli Lilly, Merck KGaA, Mirati Therapeutics, Merck Sharp & Dohme, Novocure, Novartis, Pfizer, PharmaMar, Pierre Fabre, Regeneron, Roche, Sanofi, Takeda, and Turning Point Therapeutics; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Amgen, AstraZeneca, Bayer, Gilead, Guardant Health, Janssen, Merck KGaA, Novocure, PharmaMar, Pfizer, Roche, and Takeda; support for attending meetings or travel from Gilead; and leadership or fiduciary role in other board society, committee, or advocacy group (unpaid) from British Thoracic Oncology Group, ALK Positive UK, Lung Cancer Europe, Ruth Strauss Foundation, and ETOP-IBCSG Partners Foundation Board. MCD discloses a consultant or advisory role at Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Bristol Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Takeda, Phyzer, Kyowa, Sanofi, and Janssen; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Bristol Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Takeda, Kyowa, Pierre Fabre, Novocure, Sanofi, Janssen, and Daiichi Sankyo. RGC discloses consulting fees from Roche, Novartis, Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Takeda, Janssen, GlaxoSmithKline, Amgen, Sanofi, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, and Nuvalent; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche, Novartis, Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Takeda, Janssen, GlaxoSmithKline, Amgen, Sanofi, Boehringer Ingelheim, Eli Lilly, and Johnson & Johnson; support for attending meetings and/or travel from Roche, Merck Sharp & Dohme, and Bristol Myers Squibb; participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca; and member of the Board of SEOM and SLCG. RJ discloses reimbursement for travel to meetings from Summit Therapeutics. AS discloses grants or contracts from LAM Therapeutics, Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Incyte, AbbVie, Ignyta, Takeda, MacroGenics, CytomX Therapeutics, Astex Pharmaceuticals, Prelude Therapeutics, Eli Lilly, Lepu Biopharma, Tango Therapeutics, Bristol Myers Squibb, Loxo, Gritstone, Plexxikon, Amgen, Daiichi Sankyo, ADC Therapeutics, Janssen Oncology, Rubius, Synthekine, Mersana, Blueprint Medicines, Regeneron, Alkermes, Revolution Medicines, Medikine, Black Diamond Therapeutics, BluPrint Oncology, Nalo Therapeutics, Scorpion Therapeutics, and ArriVent Biopharma; consulting fees from Incyte, Amgen, Novartis, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Takeda, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Regeneron, Eli Lilly, Black Diamond Therapeutics, Sanofi, ArriVent Biopharma, Synthekine, GlaxoSmithKline, Crispr Therapeutics, Revolution Medicines, AstraZeneca/MedImmune, Merck, Bristol Myers Squibb, and Blueprint Medicines; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from CytomX Therapeutics, AstraZeneca/ MedImmune, Merck, Takeda, Amgen, Janssen Oncology, Novartis, Bristol Myers Squibb, Bayer, Prelude Therapeutics, AbbVie, Astellas Pharma, and Eli Lilly; and leadership or fiduciary role for NEXT Virginia. MP discloses consultant fees from Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Roche, Daiichi Sankyo, Janssen, Ipsen, Esai, GlaxoSmithKline, Eli Lilly, Pfizer, Takeda, Novocure, and Nuvation Bio; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, AnHeart Therapeutics, Sanofi, Pfizer, Takeda, Janssen, Amgen, Daiichi Sankyo, and Ipsen; payment for expert testimony from Bristol Myers Squibb, AstraZeneca, Roche, and Janssen; support for attending meetings and/or travel from Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Roche, Pfizer, and Janssen; and participation on a Data Safety Monitoring Board or Advisory Board for Roche, Pharmamar, and Amgen. MN discloses consulting fees from Caris Life Sciences; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Daiichi Sankyo, Eli Lilly, Pfizer, Genentech, Bristol Myers Squibb/Mirati Therapeutics, Takeda, Johnson & Johnson, Boehringer Ingelheim, and Regeneron; and support for attending meetings and/or travel from Nuvation Bio. JLi discloses stock or stock options in AbbVie, Pfizer, Eli Lilly, Moderna, Novo-Nordisk, Cogent Bioscience, Black Diamond Therapeutics, and Kura Oncology. JG discloses grants or contracts from AbbVie, Agenus, Amgen, Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Janssen, Merck, Pfizer, Puma, RayzeBio, and Summit Therapeutics; and consulting fees from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech, Janssen, Pfizer, and Summit Therapeutics. LZ discloses speaker fees from Akeso Biopharma and Sichuan Biokin Pharmaceutical; research funding from AstraZeneca; and currently serves or has previously served as a trial chair at China Shiyao Pharm, Henrui Pharm, Kelun Pharm, Novartis, Pierre Fabre, Pfizer, QiLu Pharm, Roche, and Sichuan Biokin Pharmaceutical. HW, JLi, FCl, and ACM are employees of Summit Therapeutics and may hold stocks or stock options. All other authors declare no competing interests. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Medical writing support was provided by Megan K. Elder, PhD, and Jennifer McKinney, PhD, from MEDiSTRAVA (San Francisco, CA, USA) and was funded by Summit Therapeutics.
Reviewer disclosures
Patient reviewers on this PLSP have received honorarium from Future Oncology for their review work but have no other relevant financial relationships to disclose.
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Funding
The HARMONi-A study, which included the participants referred to as the Asian cohort, was sponsored by Akeso Biopharma. The HARMONi study was sponsored by Summit Therapeutics, Inc. Data collection in China was funded by Akeso Biopharma. Development of the original article and this plain language summary was funded by Summit Therapeutics, Inc. The sponsors were involved in the collection, analysis, and interpretation of the data as well as the development and review of this plain language summary of a publication. The authors had full access to the data and took final responsibility for the decision to publish this summary.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
